| Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript |
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q1 2025 Earnings Conference Call May 12, 2025 6:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Prathyusha Duraibabu - Chief Financial Officer Conference Call Participants Nicole Germino - Truist Luis Santos - H.C. Wainwright Operator Good afternoon and welcome to the Sangamo Therapeutics First Quarter 2025 Teleconference Call. |
seekingalpha.com |
2025-05-13 01:06:52 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates |
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.27 per share a year ago. |
zacks.com |
2025-05-12 22:55:32 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results |
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results. |
businesswire.com |
2025-05-12 22:26:00 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering |
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering. |
businesswire.com |
2025-05-12 22:23:00 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics Announces First Quarter 2025 Earnings Call |
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES FIRST QUARTER 2025 EARNINGS CALL. |
businesswire.com |
2025-05-06 20:35:00 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease |
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease. |
businesswire.com |
2025-05-06 12:30:00 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release |
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-01 15:06:31 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) |
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS TO PRESENT NEUROLOGY PIPELINE ADVANCES AT THE 28TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT). |
businesswire.com |
2025-04-28 20:31:00 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal |
Sangamo Therapeutics, Inc.'s deal with Eli Lilly to develop genomic medicines for CNS using the STAC-BBB AAV capsid brings in an $18M upfront payment and the potential to earn $1.4B in milestone payments. The Fabry Disease gene therapy program, with phase 1/2 STAAR study data expected in 1H 2025, is a major near-term catalyst for investors to keep an eye on. Positive eGFR slope data could lead to an Accelerated Approval filing of isaralgagene civaparvovec for Fabry Disease in the 2nd half of 2025. |
seekingalpha.com |
2025-04-04 18:57:37 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System |
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM. |
businesswire.com |
2025-04-03 20:01:00 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript |
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q4 2024 Earnings Conference Call March 17, 2025 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Prathyusha Duraibabu - Chief Financial Officer Conference Call Participants Luis Santos - H.C. Wainwright Maury Raycroft - Jefferies Nicole Germino - Truist Gena Wang - Barclays Operator Good afternoon, and welcome to the Sangamo Therapeutics Fourth Quarter and Full Year 2024 Teleconference Call. |
seekingalpha.com |
2025-03-17 20:29:40 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates |
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.34 per share a year ago. |
zacks.com |
2025-03-17 20:10:15 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference |
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 EARNINGS CALL AND PARTICIPATION IN UPCOMING INVESTOR CONFERENCE. |
businesswire.com |
2025-03-06 18:05:00 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile |
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO ANNOUNCES UPDATED PHASE 1/2 STAAR STUDY DATA IN FABRY SHOWING SUSTAINED BENEFIT, IMPROVEMENTS IN KIDNEY FUNCTION AND FAVORABLE SAFETY PROFILE. |
businesswire.com |
2025-02-06 10:05:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO |
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-05 16:45:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO |
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-01 12:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO |
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-30 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO |
NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ: SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-01-28 15:20:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO |
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-26 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO |
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-24 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO |
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-22 13:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO |
NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-18 14:00:00 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Sangamo Therapeutics, Inc. (SGMO) |
NEW YORK CITY, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) concerning possible violations of federal securities laws. Sangamo announced on December 30, 2024, that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be returning after the development and commercialization rights to giroctocogene fitelparvovec after deciding not to pursue commercialization of the asset, which is in phase 3. |
accessnewswire.com |
2025-01-17 11:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO |
NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-01-16 20:45:00 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Sangamo Therapeutics, Inc. (SGMO) |
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) concerning possible violations of federal securities laws. Sangamo announced on December 30, 2024, that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be returning after the development and commercialization rights to giroctocogene fitelparvovec after deciding not to pursue commercialization of the asset, which is in phase 3. |
accesswire.com |
2025-01-15 12:30:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out |
NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sangamo Therapeutics, Inc. ("Sangamo" or "the Company") (NASDAQ:SGMO). Investors who purchased Sangamo securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SGMO. |
accesswire.com |
2025-01-15 12:00:00 |
Czytaj oryginał (ang.) |
| Did Sangamo Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SGMO |
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) concerning possible violations of federal securities laws. Sangamo announced on December 30, 2024, that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be returning after the development and commercialization rights to giroctocogene fitelparvovec after deciding not to pursue commercialization of the asset, which is in phase 3. |
accesswire.com |
2025-01-14 12:30:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sangamo Therapeutics, Inc. ("Sangamo" or "the Company") (NASDAQ:SGMO). Investors who purchased Sangamo securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SGMO. |
accesswire.com |
2025-01-14 12:00:00 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics, Inc. (SGMO) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates |
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) concerning possible violations of federal securities laws. Sangamo announced on December 30, 2024, that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be returning after the development and commercialization rights to giroctocogene fitelparvovec after deciding not to pursue commercialization of the asset, which is in phase 3. |
accesswire.com |
2025-01-13 12:30:00 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sangamo Therapeutics, Inc. ("Sangamo" or "the Company") (NASDAQ:SGMO). Investors who purchased Sangamo securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SGMO. |
accesswire.com |
2025-01-13 12:00:00 |
Czytaj oryginał (ang.) |
| SGMO ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Sangamo Therapeutics, Inc. |
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) concerning possible violations of federal securities laws. Sangamo announced on December 30, 2024, that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be returning after the development and commercialization rights to giroctocogene fitelparvovec after deciding not to pursue commercialization of the asset, which is in phase 3. |
accesswire.com |
2025-01-12 14:13:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO |
NEW YORK CITY, NY / ACCESSWIRE / January 12, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2025-01-12 14:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Investigates Possible Securities Fraud Violations by Sangamo Therapeutics, Inc. (SGMO) |
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) concerning possible violations of federal securities laws. Sangamo announced on December 30, 2024, that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be returning after the development and commercialization rights to giroctocogene fitelparvovec after deciding not to pursue commercialization of the asset, which is in phase 3. |
accesswire.com |
2025-01-12 13:00:00 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SGMO |
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) concerning possible violations of federal securities laws. Sangamo announced on December 30, 2024, that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be returning after the development and commercialization rights to giroctocogene fitelparvovec after deciding not to pursue commercialization of the asset, which is in phase 3. |
accesswire.com |
2025-01-03 14:20:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO |
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2025-01-03 14:00:00 |
Czytaj oryginał (ang.) |
| Lost Money on Sangamo Therapeutics, Inc. (SGMO)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) concerning possible violations of federal securities laws. Sangamo announced on December 30, 2024, that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be returning after the development and commercialization rights to giroctocogene fitelparvovec after deciding not to pursue commercialization of the asset, which is in phase 3. |
accesswire.com |
2025-01-03 12:30:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESSWIRE / January 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sangamo Therapeutics, Inc. ("Sangamo" or "the Company") (NASDAQ:SGMO). Investors who purchased Sangamo securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SGMO. |
accesswire.com |
2025-01-03 12:00:00 |
Czytaj oryginał (ang.) |
| Investors who lost money on Sangamo Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - SGMO |
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) concerning possible violations of federal securities laws. Sangamo announced on December 30, 2024, that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be returning after the development and commercialization rights to giroctocogene fitelparvovec after deciding not to pursue commercialization of the asset, which is in phase 3. |
accesswire.com |
2025-01-02 23:20:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO |
NEW YORK , Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ: SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-01-02 23:05:00 |
Czytaj oryginał (ang.) |
| Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm |
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON SANGAMO THERAPEUTICS, INC. (SGMO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Hap. |
businesswire.com |
2025-01-02 20:00:00 |
Czytaj oryginał (ang.) |
| Investors who lost money on Sangamo Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - SGMO |
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) concerning possible violations of federal securities laws. Sangamo announced on December 30, 2024, that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be returning after the development and commercialization rights to giroctocogene fitelparvovec after deciding not to pursue commercialization of the asset, which is in phase 3. |
accesswire.com |
2025-01-02 18:15:00 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation |
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SANGAMO THERAPEUTICS, INC. (SGMO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your leg. |
businesswire.com |
2025-01-02 18:00:00 |
Czytaj oryginał (ang.) |
| Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz |
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON SANGAMO THERAPEUTICS, INC. (SGMO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On December 30, 2024, after market hours, Sangamo d. |
businesswire.com |
2025-01-02 17:05:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Investors to Inquire about Securities Investigation |
NEW YORK CITY, NY / ACCESSWIRE / January 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sangamo Therapeutics, Inc. ("Sangamo" or "the Company") (NASDAQ:SGMO). Investors who purchased Sangamo securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SGMO. |
accesswire.com |
2025-01-02 12:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO |
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-31 19:53:00 |
Czytaj oryginał (ang.) |
| Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet |
U.S. stocks traded slightly lower midway through trading, with the Nasdaq Composite falling around 50 points on Tuesday. |
benzinga.com |
2024-12-31 14:01:49 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics' stock falls the most in 16 years after Pfizer ends Hemophilia pact |
The small-cap won't receive an expected payout in the first quarter, creating a cash overhang. |
marketwatch.com |
2024-12-31 13:22:00 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact |
Sangamo Therapeutics (SGMO) shares cratered more than 50% Tuesday, a day after the biopharma firm announced that Pfizer (PFE) had pulled out of its deal to co-develop a hemophilia drug. |
investopedia.com |
2024-12-31 13:20:39 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact |
On Monday, Sangamo Therapeutics, Inc. SGMO regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc PFE. |
benzinga.com |
2024-12-31 11:14:19 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session |
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Tuesday. |
benzinga.com |
2024-12-31 10:47:22 |
Czytaj oryginał (ang.) |
| SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate |
Sangamo stock crashes 60.4% as partner Pfizer decides to end collaboration for hemophilia A candidate, giroctocogene fitelparvovec. |
zacks.com |
2024-12-31 09:10:54 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics down 50% premarket on Pfizer blow |
Shares in Sangamo Therapeutics dropped 50% premarket after Pfizer Inc (NYSE:PFE, ETR:PFE) ended its collaboration on a gene therapy for haemophilia The drug, giroctocogene fitelparvovec, met its target in a late-stage trial, with Pfizer previously expected to seek regulatory approval in 2025. “We were extremely surprised and very disappointed,” said Sangamo's CEO, Sandy Macrae. |
proactiveinvestors.co.uk |
2024-12-31 08:06:59 |
Czytaj oryginał (ang.) |
| Sangamo to reclaim hemophilia A therapy rights post Pfizer termination |
Sangamo Therapeutics said on Monday it would regain full rights to its hemophilia A gene therapy after co-development partner Pfizer terminated the agreement. |
reuters.com |
2024-12-30 18:34:58 |
Czytaj oryginał (ang.) |